SCHEMBL15100717

SCHEMBL15100717

COc1ccc(C(=O)c2c(C)c(C)n(C)c2C)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.55
▸ NPSR1 Q6W5P4 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ MEN1 O00255 1/20 0.50
▸ MAPT P10636 1/20 0.50
▸ MAPK1 P28482 1/20 0.50
▸ RAB9A P51151 1/20 0.50
▸ RXFP1 Q9HBX9 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ CES2 O00748 1/20 0.48
▸ CES1 P23141 1/20 0.48
▸ CA1 P00915 4/20 0.47
▸ CA2 P00918 4/20 0.47
▸ ALDH1A1 P00352 4/20 0.47
▸ ALOX15 P16050 2/20 0.47
▸ HTT P42858 1/20 0.47
▸ GAA P10253 1/20 0.46
▸ PARP1 P09874 1/20 0.46
▸ PARP10 Q53GL7 1/20 0.46
▸ PARP2 Q9UGN5 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11018074 0.80 ALDH1A1 (0.49) LMNANPSR1KMT2AMEN1MAPT
SCHEMBL15197089 0.80 TP53 (0.50) LMNANPSR1KMT2AMEN1MAPT
SCHEMBL1287917 0.78 CNR1 (0.60) MAPTCYP2C19
SCHEMBL10877250 0.75 ALDH1A1 (0.49) LMNANPSR1KMT2AMEN1MAPT
SCHEMBL51509 0.75 RXFP1 (0.79) LMNANPSR1KMT2AMEN1MAPT
SCHEMBL9418310 0.75 RXFP1 (0.79) LMNANPSR1KMT2AMEN1MAPT
SCHEMBL8403575 0.75 LMNA (0.45) LMNANPSR1KMT2AMEN1MAPT
SCHEMBL8403244 0.73 NPSR1 (0.50) LMNANPSR1KMT2AMEN1MAPT
SCHEMBL18997010 0.72 KMT2A (0.53) LMNANPSR1KMT2AMEN1MAPT
SCHEMBL758577 0.72 LMNA (0.70) LMNANPSR1KMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 — — US disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 — — US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 — — US disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 — — US disclosed
EP-2612848-A1 CYCLIC AMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2013-07-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 LMNA 1477/4885NPSR1 1330/4885KMT2A 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback